- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04668118
The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry Eye
May 31, 2022 updated by: Peking University Third Hospital
This study aims to evaluate the efficacy and safety of 3% Diquafosol Ophthalmic Solution for visual display terminal (VDT)-associated dry eye and to investigate the mechanism of treatment.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The treatment period is 12 weeks.
The day after subjects who meet the inclusion criteria undergo baseline examination is the day starting the medication.
The dosing frequency was six times daily for 3% Diquafosol Ophthalmic Solution.
The follow-up time points are 2, 4, 8, 12 weeks, and the investigator will evaluate the symptoms and signs of Dry Eye.
Study Type
Interventional
Enrollment (Anticipated)
68
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hong Qi, Phd
- Phone Number: 010-13901066889
- Email: doctorqihong@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Recruiting
- Peking University Third Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 38 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female with a diagnosis dry eye based on Chinese Dry Eye Diagnosis Standard (2020);
- Working in the offices with VDTs more than 4h daily;
- Working in the offices with VDTs at least five days per week;
- Provision of written informed consent.
Exclusion Criteria:
- Known allergy to any eye drops
- Ocular therapies other than artificial tears
- Presence of any of the following conditions: active ocular infection, ocular inflammation, active ocular allergy, contact lens wear, ocular surgical history, laser treatment in the last 3 months, Meibomian gland dysfunction (MGD) over grade 2 (the grade is according to the report of the International Workshop on MGD in 2011), severe blepharitis or obvious inflammation of the eyelid margin, which in the judgment of the investigator may interfere with the interpretation of the study results
- Pregnant and lactating women, or those planning a pregnancy over the course of the study
- Uncontrolled systemic disease
- Hypersensitivity or intolerance to diquafosol(DQS)
- Subjects with a history of anxiety and depression
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diquafosol group
The treatment period is 12 weeks.
The day after subjects who meet the inclusion criteria undergo baseline examination is the day starting the medication.
Dosing frequency was six times daily for 3% Diquafosol Ophthalmic Solution.
The follow-up time points are 2, 4, 8, 12 weeks, and no other medication is required on the follow-up day.
|
As a P2Y2 receptor agonist, diquafosol can be used to stabilize the tear film by stimulating P2Y2 receptors on the corneal epithelial cells and conjunctival goblet cell, which increase the secretion of tear fluid and mucin on the ocular surface, thereby repairing the ocular surface and stabilizing the tear film.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the changes of Ocular Surface Disease Index (OSDI) scores
Time Frame: 12 weeks after intervention
|
OSDI is one of the most frequently used questionnaires for evaluation of Dry eye disease(DED).
This includes 12 questions which measure the frequency of symptoms over the recent week, and the scores range from 0 to 100.
The higher the score, the worse the result.
|
12 weeks after intervention
|
the changes of Tear break-up time (TBUT)
Time Frame: 12 weeks after intervention
|
TBUT is the time from normal blinking to the first appearance of a break in the tear film.
The BUT was measured using fluorescein with a metronome, and the average of three consecutive BUTs was calculated.
The shorter the TBUT, the worse the outcome.
|
12 weeks after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the changes of scores of Corneal fluorescein staining (CFS)
Time Frame: 12 weeks after intervention
|
The degree of fluorescein staining of the cornea was evaluated using the National Eye Institute (NEI) scale of five corneal regions (central, superior, temporal, nasal, and inferior).
The degree of staining in each of the five regions was graded on a scale of 0-3 according to the NEI/Industry Workshop method: 0 =no staining, 1 =mild staining, 2 = moderate staining, and 3 = severe staining.
The maximal score for each area was 3. The scores of the five areas were added to obtain a total score for each eye.
The higher the score, the worse the result.
|
12 weeks after intervention
|
the changes of scores of Lissamine green staining
Time Frame: 12 weeks after intervention
|
To grade the temporal zone, the subject looks nasally; to grade the nasal zone the subject looks temporally.
The upper and lower conjunctiva can also be graded.
The higher the score, the worse the result.
|
12 weeks after intervention
|
the changes of value of Schirmer Ⅰ test (SⅠt)
Time Frame: 12 weeks after intervention
|
The Schirmer I test is performed using sterile strips without anesthesia.
The strips are placed in the lateral part of the inferior fornix of the eye for 5min and the extent of tear flow down was measured in millimeters.
The higher the value, the better the result.
|
12 weeks after intervention
|
the changes of Lipid layer thickness(LLT)
Time Frame: 12 weeks after intervention
|
Lipid layer is evaluated by Lipiview interferometer (TearScience Inc, Morrisville, NC, USA) which records a 15-s live digital image of the interference pattern of the tear film.
The interferometry color units (ICU) of the tear film which is an indicator of lipid layer thickness is assessed according to the mean interference color pattern through specular reflection.
The higher the thickness, the better the result.
|
12 weeks after intervention
|
the changes of Partial blink rate(PBR)
Time Frame: 12 weeks after intervention
|
PBR can be provided by Lipiview interferometer, which mainly evaluate incomplete blinking.
The higher the rate, the worse the result.
|
12 weeks after intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Tingting Yang, MD, Peking University Third Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2021
Primary Completion (Anticipated)
October 1, 2022
Study Completion (Anticipated)
March 25, 2023
Study Registration Dates
First Submitted
December 6, 2020
First Submitted That Met QC Criteria
December 14, 2020
First Posted (Actual)
December 16, 2020
Study Record Updates
Last Update Posted (Actual)
June 1, 2022
Last Update Submitted That Met QC Criteria
May 31, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Diquafosol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Syndromes
-
Singapore National Eye CentreCompleted
-
Singapore National Eye CentreCompleted
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
OptovueCompleted
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
He Eye HospitalCompleted
-
Johnson & Johnson Vision Care, Inc.Completed
Clinical Trials on Diquafosol
-
Mun Wai LeeSanten OyRecruiting
-
He Eye HospitalSanten Pharmaceutical(China) Co.,LTDNot yet recruiting
-
Chong Kun Dang PharmaceuticalCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted